title: [New therapeutic era in heart failure with reduced ejection fraction: Which population of French patients is concerned?].
abstract: A new class of cardiovascular drugs, angiotensin receptor neprilysin inhibitors, has shown its efficacy in the PARADIGM-HF study in replacement of renin-angiotensin blockers in symptomatic heart failure patients with reduced ejection fraction, and already treated according to the recommendations. Recent French epidemiological data in the literature allow assessing the number of French patients who could be concerned by the new treatment in taking account the different parameters from the PARADIGM-HF study.
authors.affiliation: Département de cardiologie, institut Lorrain du cœur et des vaisseaux, CHU Nancy-Brabois, 54500 Vandœuvre-lès-Nancy, France. Electronic address: yves.juilliere@wanadoo.fr.
authors.forename: Y
authors.initials: Y
authors.lastname: Juillière
authors.affiliation: Département de cardiologie B et département d'épidémiologie, UMR Inserm 1027, CHU de Toulouse, 31000 Toulouse, France.
authors.forename: J
authors.initials: J
authors.lastname: Ferrières
mesh_terms: D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use*; D005602:France / Q000453:epidemiology; D006333:Heart Failure / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D006801:Humans; D015260:Neprilysin / Q000037:antagonists & inhibitors*; D016032:Randomized Controlled Trials as Topic; D013318:Stroke Volume / Q000502:physiology*
chemical_list: D057911:Angiotensin Receptor Antagonists; D015260:Neprilysin
keywords: Angiotensin recepteur neprilysin inhibitors; Epidemiology; Heart failure with reduced ejection fraction; Inhibiteur de l’angiotensine II et de la néprilysine; Insuffisance cardiaque à fraction d’éjection réduite; Épidémiologie